Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Palatin Technologies, Inc.'s (PTN) shares were losing more than 38 percent in pre-market activity on the NYSE after the biopharmaceutical company announced that co-primary sign endpoint and secondary sign endpoints in its PL9643 MELODY-1 pivotal Phase 3 clinical trial in dry eye disease did not achieve statistical significance.
Taming the Immune System When Rare Diseases Strike genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
Palatin s Focus is Solely on the Development of its Melanocortin Receptor (MCR) System Pipeline PL9643 MELODY-1 Pivotal Phase 3 Study in Dry Eye Disease (DED).